CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 119 enrolled
Drug / intervention
EVO101drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05579899
NCT05579899Phase 2Completed

A Randomized, Vehicle-controlled, Safety and Efficacy Study of EVO101 in Adult Subjects With Atopic Dermatitis

Evommune, Inc.·interventional·Posted Oct 14, 2022·Updated Mar 5, 2025

In Brief

A Phase 2 clinical trial evaluating EVO101 for Atopic Dermatitis Eczema. Completed, enrolled 119 participants across 21 sites.

Detailed Summary

This is a Phase 2a safety and efficacy study of EVO101 for the treatment of adults with atopic dermatitis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedOct 14, 2022
Enrollment StartSep 27, 2022
Primary CompletionJul 27, 2023
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 3.7 years ago

Interventions

EVO101drug

Topical Cream